Science Explorer Back to mapMap
Institution · Moberg Pharma (Sweden)

Most cited papers from Moberg Pharma (Sweden)

What are the most cited papers from Moberg Pharma (Sweden)?

The most cited paper from Moberg Pharma (Sweden) is "A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*" (Boni Elizabeth Elewski et al., 2020), with 42 citations. Next come "Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24‐week, double‐blind, placebo‐controlled study" (30) and "Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double‐blind, randomised, placebo‐controlled studies" (30).

Showing 12 of 12 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail* Boni Elizabeth Elewski et al. · British Journal of Dermatology 18 May 2020 42
2 Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24‐week, double‐blind, placebo‐controlled study Lennart Emtestam, Taavi Kaaman, Kjell Rensfeldt · Mycoses 11 Jun 2012 30
3 Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double‐blind, randomised, placebo‐controlled studies Lennart Emtestam, Åke Svensson, Kjell Rensfeldt · Mycoses 4 Oct 2011 30
4 Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study Aditya Gupta, Maria S. Surprenant, Steven E. Kempers et al. · Journal of the American Academy of Dermatology 22 Jun 2020 29
5 The Voting System in the Council of the European Union. The Balance Between Large and Small Countries1 Axel Moberg · Scandinavian Political Studies Nov 1998 16
6 The effect of K101 Nail Solution on Trichophyton rubrum and Candida albicans growth and ultrastructure Kjell R. Hultenby, Erja Chryssanthou, Lena Klingspor et al. · Mycoses Open access 17 Jun 2014 15
7 A cost-utility analysis of two Clostridioides difficile infection guideline treatment pathways Nicholas Swart, Araadhna M. Sinha, Anthony Bentley et al. · Clinical Microbiology and Infection Open access 24 Jun 2023 13
8 Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis Bianca Maria Piraccini, Michela Valeria Rita Starace, Anders Dyhr Toft · Dermatology Open access 2017 10
9 Early and Visible Improvements after Application of K101 in the Appearance of Nails Discoloured and Deformed by Onychomycosis Jan Faergemann, Sören Gullstrand, Kjell Rensfeldt · Journal of Cosmetics Dermatological Sciences and Applications Open access 2011 10
10 Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis Amir Tavakkol, Janet C. DuBois, Aditya Kumar Gupta · Antimicrobial Agents and Chemotherapy Open access 19 Aug 2024 4
11 Rapid cosmetic improvements in nail psoriasis patients treated with K101-03 Bianca Maria Piraccini, Michela Valeria Rita Starace, Anders Dyhr Toft · European Journal of Dermatology Mar 2018 4
12 Rapid Visible Improvements in Onychomycosis: An Open-Label Clinical Investigation of Kerasal NailTM Jiun Yit Pan, Chris Lixian Tan, Anders Dyhr Toft · Journal of Cosmetics Dermatological Sciences and Applications Open access 2017 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.